Acute Otitis Media
This presentation is the property of its rightful owner.
Sponsored Links
1 / 20

Acute Otitis Media PowerPoint PPT Presentation


  • 110 Views
  • Uploaded on
  • Presentation posted in: General

Acute Otitis Media. Otitis Media with Effusion. It is estimated that in the US 24,000,000 AOM episodes occur yearly 6% failures ~1,500,000 failures. AOM : Spectrum of Pathogens. S. pneumoniae25  40% H. influenzae20  35% M. catarrhalis5  20% S. pyogenes 2  5%.

Download Presentation

Acute Otitis Media

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Acute otitis media

Acute Otitis Media


Otitis media with effusion

Otitis Media with Effusion


Acute otitis media

It is estimated that in the US

24,000,000 AOM episodes

occur yearly

6% failures ~1,500,000

failures


Aom spectrum of pathogens

AOM : Spectrum of Pathogens

S. pneumoniae25  40%

H. influenzae20  35%

M. catarrhalis5  20%

S. pyogenes 2  5%


Risk factors for failure regardless of antibiotic

Risk factors for failure regardless of antibiotic

  • Age <2 years

  • Daycare

  • Recurrent AOM

  • Recurrent antibiotics in past 3 months

  • Mixed viral and bacterial infection

  • Mixed S. pneumoniae and H. influenzae infection

Leibovitz & Dagan. Infect Med 2001; 18:212–216.


The goals of antibacterial therapy

The goals ofantibacterial therapy

Maximize clinical outcome by maximizing therapeutic effect

Maximum reduction in bacterial load at site of

infection, with aim of bacterial eradication

Minimize potential for emergence and selection of resistance

Maximize cost–benefit of treatment

Reduce the number of

individuals carrying

resistant bacteria

Minimize spread

of resistance


Persistence of pathogens in mef day 2 7 placebo

Persistence of Pathogens in MEF Day 2-7 - Placebo

S. pneumoniae

H. influenzae

Howie & Ploussard, Clin Pediatr 1972; 11:205-14


The pollyanna phenomenon

The “Pollyanna Phenomenon”

Marchant et al, J Pediat 120:72-7, 1992

Bacteriologic efficacy

in bacterial AOM

Clinical efficacy

in clinical AOM

Clinical efficacy

in bacterial AOM

Placebo


Acute otitis media

Some drugs work better than others

in bacteriologic eradication in AOM

Eradication is associated with improved clinical outcome


Acute otitis media

b

a

c

TYMPANOCENTESIS

CULTURE

The Double-Tympanocentesis Method

TREATMENT

day 1

day 4-6

day 10-12

day 21-30


Acute otitis media

62

52

40

21

15

10

9

2/22

4/41

4/19

18/29

34/85

7/46

Pnc - S

Pnc - I, R

Hi

Placebo

Cefaclor vs. Cefuroxime-Axetil: Bacteriology and Organism-specific Bacteriological Failure

CEF - AXET

CECL

84

Pnc

Hi

% bacteriologic failures

Placebo

Dagan et al, J Infect Dis 176:1253-1259, 1997

Dagan et al AAC 44:43-50, 2000


Acute otitis media

73

50

0

0

0/9

11/15

0/28

6/12

Bacteriologic Failure Rate (day 4-5) TMP/SMX

as an Example of “All-or-Non Phenomenon”

MIC<=0.5 mcg/ml

84

MIC >0.5 mcg/ml

52

% bacteriologic failures

Pnc

Placebo Pnc

Hi

Placebo Hi

Leiberman et al, Pediatr Infect Dis, 20:260-4, 2001


Bacteriological eradication of baseline pathogens at day 4 to 6 by patient and treatment group

Bacteriological Eradication of Baseline Pathogens at day 4 to 6 by Patient and Treatment Group

Augmentin

Azithromycin

P= 0.0001

P= 0.1

P= 0.26

P < 0.0001

% with bacteriologic success

54/65

35/71

26/30

13/33

18/20

13/19

10/15

9/19


Acute otitis media

6/6

3 days (Dagan et al AAC 44:43-50, 2000)

100

0.25

5 days (Dagan et al PIDJ 19:95-104, 2000)

0.25

5/8

11/17

23/36

11/18

5/9

65

64

63

61

56

2/25

0/12

8

0

<= 0.25

> 2.0

0.5 - 1

2.0 - 4.0

Bacteriologic Failure Rate (day 4-6)

for Azithromycin

Pnc

Hi

100

90

84

80

70

60

52

% with bacteriological failure

50

40

30

20

10

0

Placebo

Placebo

Azithromycin MIC (µg/ml)

For placebo - Howie, Clin Pediatr 11:205-14,1972


Acute otitis media

Amox/CA 45

Amox/CA 90

6.3

2

5/80

2/117

Amox/Clav Pk/Pd: Regular dose (45mg/Kg/d) vs. High Dose (90mg/Kg/d): Bacteriological Failures

Hi

23.1

P = 0.01

% Bacteriologic persistence

Pnc

6

9/39

5/80

Dagan et al. Pediatr Infect Dis J 19:95–104, 2000

Dagan et al, Pediatr Infect Dis J 20:829-37, 2001


Acute otitis media

Does all this

matter?


Clinical success augmentin vs azithromycin

Clinical Success: Augmentin vs. Azithromycin

Augmentin

Azithromycin

P=0.01

P=0.023

% with clinical success

80

58

87

39

83

49

Dagan et al Pediatr Inf Dis J Feb 00


Acute otitis media

How to choose

antibiotics for AOM?


Acute otitis media

AOM

1st AOM

Recurrent or

non-responsive

AOM

(no AOM in last 3 m)

  • Amox (40 - 100)

  • A/C (40 - 90)

  • Cefurox axetil

  • Ceftriaxone (1/3 doses)

  • (if unable to take PO)

  • Amox (80 - 100)

  • A/C (90)

  • Cefurox axetil

  • Ceftriaxone (3 doses)


Acute otitis media

Hold fire !!

Easier on the

trigger

  • age >= 2 yrs

  • purulent rhinitis + SOM

  • no fever, mild symptoms

  • 1st AOM

  • age < 1 yr

  • bulging yellow (pus) ear drum

  • DCC attendee

  • recurrent/non-responsive AOM

  • high fever, toxic-appearing

  • genetic risk factors

  • anatomic risk factors


  • Login